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Abstract
Background: Sheeppox (SPP) and goatpox (GTP) caused by sheeppox virus (SPPV) and goatpox virus (GTPV),
respectively of the genus Capripoxvirus in the family Poxviridae, are severely afflicting small ruminants’ production
systems in Africa and Asia. In endemic areas, SPP and GTP are controlled using vaccination with live attenuated
vaccines derived from SPPV, GTPV or Lumpy skin disease virus (LSDV).
Sometimes outbreaks occur following vaccination. In order to successfully control the spread of the virus, it is
essential to identify whether the animals were infected by the field strain and the vaccine did not provide sufficient
protection. Alternatively, in some cases the vaccine strain may cause adverse reactions in vaccinated animals or in
rare occasions, re-gain virulence. Thus, diagnostic tools for differentiation of virulent strains from attenuated vaccine
strains of the virus are needed.
The aim of this study was to identify an appropriate diagnostic target region in the capripoxvirus genome by
comparing the genomic sequences of SPPV field isolates with those of the most widely used SPP vaccine strains.
Results: A unique 84 base pair nucleotide deletion located between the DNA ligase gene and the VARV B22R
homologue gene was found only in SPPV vaccines derived from the Romanian and Yugoslavian RM/65 strains and
absent in SPPV field isolates originated from various geographical locations of Asia and Africa.
In addition, we developed and evaluated a conventional PCR assay, exploiting the targeted intergenic region to
differentiate SPPV vaccine virus from field isolates. The assay produced an amplicon size of 218 bp for the vaccine
strains, while the SPPV field isolates resulted in a 302 bp PCR fragment. The assay showed good sensitivity and
specificity, and the results were in full agreement with the sequencing data of the PCR amplicons.
Conclusion: The developed assay is an improvement of currently existing diagnostic tools and, when combined
with a capripox virus species-specific assay, will enhance SPP and GTP diagnosis and surveillance and facilitate
epidemiological investigations in countries using live attenuated SPP vaccines. In addition, for laboratories with
limited resources, the assay provides a simple and cost-effective alternative for sequencing.
Keywords: CaPV, Sheeppox vaccine, Sheeppox virus, VARV B22R homologue gene, DNA ligase gene
* Correspondence: C.Lamien@iaea.org
1Animal Production and Health Laboratory, Joint FAO/IAEA Agricultural and
Biotechnology laboratory, Division of Nuclear Techniques in Food and
Agriculture, Department of Nuclear Sciences and Applications, International
Atomic Energy Agency, Wagramer Strasse 5, P.O. Box 100, A1400 Vienna, Austria
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Chibssa et al. Virology Journal  (2018) 15:59 
https://doi.org/10.1186/s12985-018-0969-8
Background
Sheeppox (SPP) and goatpox (GTP) are caused by sheep-
pox virus (SPPV) and goatpox virus (GTPV) of the genus
Capripoxvirus of the family Poxviridae [1]. In endemic
areas SPP and GTP have a serious economic impact on
small ruminant production systems, causing losses in
productivity, mortality, damaging skins and hides, as well
as inflicting international trade restrictions [2]. They are
listed in the group of economically important animal dis-
eases for which outbreaks have to be notified immediately
to the World Organization for Animal Health [3].
The main mode of virus transmission is the direct
contact between diseased and non-infected animals, but
indirect transmission may also occur [4]. Clinical signs of
SPPV and GTPV infections are characterized by ocular
and nasal discharge and pock-like lesions in the skin and
mucosae of the respiratory and gastrointestinal tracts [2,
4, 5]. Most of the isolates are host specific and cause dis-
ease mainly in sheep or in goats, whereas some isolates
can cause serious disease in both animal species [6].
SPP and GTP are endemic in many African, Middle East-
ern and Asian countries and recurrent epidemics have oc-
curred in Greece and Bulgaria in 2013–2014 [7] and in
Greece in 2016 and 2017. SPPV is also circulating in the Rus-
sian Federation where it causes sporadic outbreaks of disease.
In endemic regions, control of the disease is through
effective immunization using killed or live attenuated
vaccines derived from SPPV, GTPV or Lumpy skin dis-
ease virus (LSDV). In general, live attenuated vaccines
are the better choice as compared to inactivated vac-
cines, as they confer long-lasting immunity. For instance,
the Yugoslavian RM65, the Romanian Fanar and
KSGP0240 strains, the most commonly used vaccines
strains against SPPV, are reported to provide high levels
of protection [7]. The Yugoslavian RM65 is widely used
in the Middle East, Asia and in the Horn of Africa, while
the Romanian Fanar is used in India and Maghreb coun-
tries. The Yugoslavian RM65 was attenuated by 30 serial
passages on ovine kidney cells, and the Romanian Fanar
by 26 serial passages on lamb testis cells [7].
The KSGP 0240 is widely used in several endemic re-
gions in Africa. Nevertheless, KSGP0240 has been shown,
by sequencing, to be a LSDV, thus, it can be differentiated
from virulent isolates of SPPV using available capripox-
virus genotyping methods [7].
However, when using live attenuated vaccines, the epi-
demiological investigation of outbreaks can become quite
challenging. When outbreaks occur following vaccination,
it is essential to identify whether the animals were infected
by the field strain because the vaccine did not provide suf-
ficient protection. Alternatively, in some cases the vaccine
strain may cause adverse reactions in vaccinated animals
or, in rare occasions, re-gain the virulence as suggested by
Lee and co-workers for herpesvirus vaccine [8].
Unfortunately, the current live attenuated capripox
(CaP) vaccines do not offer the possibility to differentiate
vaccinated animals from infected ones. This creates a
need to identify a suitable genomic target and develop
molecular tools that would enable the differentiation of
SPPV field isolates from vaccine strains to rule out the
involvement of SPP vaccines during a CaP outbreak in a
vaccinated herd. Such a tool will facilitate the manage-
ment and control of CaP infections in small ruminants.
The present study describes the use of a suitable diag-
nostic target of the SPPV genome to develop an assay
that can discriminate SPP vaccines derived from the Ro-
manian and the Yugoslavian RM/65 strains from SPPV
field isolates, to facilitate the diagnosis and surveillance
of capripox virus (CaPV) infections in small ruminants.
Methods
Virus and nucleic acid extraction
The information related to the field isolates and vaccine
strains of SPPV as well as other CaPVs used in this study
are presented in Table 1. Viral multiplication was per-
formed on embryonic skin cell from sheep (ESH-L cells)
grown in Hank’s Minimum Essential Medium (MEM)
supplemented with 10% foetal calf serum and 1% antibi-
otics. DNA was extracted from infected cell culture super-
natants and clinical samples using the AllPrep DNA/RNA
extraction kit (QIAGEN) following the manufacturer’s in-
structions. Extracted DNA was eluted with 80 μl elution
buffer and stored at − 20 °C until further use.
Primer design and PCR
The target region was selected based on the alignment of
the full genomes of three SPPVs, Sheeppox virus 10,700–99
(AY077832), Sheeppox virus A (AY077833) and Sheeppox
virus NISKHI, (AY077834), retrieved from GenBank, and
the unpublished genome of the Romanian vaccine strain
used in Morocco. PCR primers, flanking a unique nucleo-
tide deletion in the Romanian vaccine strain, were designed
using Primer3Plus online tool. The target was an intergenic
region located between the DNA ligase gene and the VARV
B22R homologue gene of CaPVs corresponding to position
121,500–122,799 of SPPV A (AY077833). The primers
(Table 2) were designed to amplify amplicons of 302 bp in
SPPV field isolates and 218 bp fragments for SPPV vac-
cines. The specificity of the primers was checked by using
the Basic Local Alignment Search Tool (BLAST). The
primers were synthesized and purified by HPLC by
Eurofins Genomics (Austria).
PCR was conducted in a reaction volume of 20 μl,
containing 500 nM of each forward and reverse primers,
0.2 mM dNTPs, 2.5 U Taq DNA polymerase (QIAGEN),
1× PCR buffer, and 2 μl template DNA. The cycling con-
ditions were as follow: 95 °C for 4 min followed by 35 cy-
cles of 95 °C for 30 s, 58 °C for 30 s, and 72 °C for 30 s
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Table 1 List of capripoxvirus isolates used in this study
Sample No. Isolate/Strain name Source Sample type Country Collection-date Host
1 SPPV Morocco vaccine Biopharma/Morocco Cell culture Morocco Unknown Sheep
2 SPPV Algeria vaccine Lot/7 INMV-LCV/Algeria Cell culture Algeria Unknown Sheep
3 SPPV Senegal vaccine LNERV-ISRA/Senegal Cell culture Iran 1966 Sheep
4 SPPV PANVAC/6 vaccine PANVAC/Ethiopia Cell culture Kenya 2010 Sheep
5 SPPV Turkey/98 Corum VCRI-Pendik/Turkey Cell culture Turkey 1998 Sheep
6 SPPV Oman/84 IAH-Pirbright/UK Cell culture Oman 1984 Sheep
7 SPPV Turkey/98 Denizli VCRI-Pendik/Turkey Cell culture Turkey 1998 Sheep
8 SPPV Algeria/93 Djelfa INMV-LCV/Algeria Cell culture Algeria 1993 Sheep
9 SPPV Algeria/05 Illizi INMV-LCV/Algeria Cell culture Algeria 2005 Sheep
10 SPPV Turkey/98 Sivas VCRI-Pendik/Turkey Cell culture Turkey 1998 Sheep
11 SPPV MOG/SP/T/2/07 IVM/Mongolia Skin scrapping Mongolia 2007 Sheep
12 SPPV MOG/SP/T/3/07 IVM/Mongolia Skin scrapping Mongolia 2007 Sheep
13 GTPV Iraq/61 Gorgan IAH-Pirbright/UK Cell culture Iraq 1961 Goat
14 GTPV MOG/GP/T/6/08 IVM/Mongolia Skin scrapping Mongolia 2008 Goat
15 GTPV MOG/GP/L/5/08 IVM/Mongolia Skin scrapping Mongolia 2008 Goat
16 GTPV Awi/O13/2011 NAHDIC/Ethiopia Skin scrapping Ethiopia 2011 Goat
17 GTPV Bale/O14/2007 NAHDIC/Ethiopia Skin scrapping Ethiopia 2007 Goat
18 GTPV Giner/O15/2007 NAHDIC/Ethiopia Skin scrapping Ethiopia 2007 Goat
19 LSDV KS-1 HSL-AGES/Austria Cell culture Kenya 1976 Sheep
20 LSDV Egypt/89 Ismalia HSL-AGES/Austria Cell culture Egypt 1989 Cattle
21 LSDV Guder/B5/2008 NAHDIC/Ethiopia Skin scrapping Ethiopia 2008 Cattle
22 LSDV Humbo/B23/2010 NAHDIC/Ethiopia Skin scrapping Ethiopia 2010 Cattle
23 SPPV Algeria vaccine Lot/10 INMV-LCV/Algeria Cell culture Algeria Unknown Sheep
24 SPPV Mauritania/85 Gorgol LNERV-ISRA/Senegal Cell culture Mauritania 1985 Sheep
25 SPPV Turkey/98 Darica VCRI-Pendik/Turkey Cell culture Turkey 1998 Sheep
26 SPPV MOG/SP/T/1/2006 IVM/Mongolia Skin scrapping Mongolia 2006 Sheep
27 GTPV Saudi Arabia/93 IAH-Pirbright/UK Cell culture Saudi Arabia 1993 Goat
28 SPPV Nigeria/77 IAH-Pirbright/UK Cell culture Nigeria 1993 Sheep
29 GTPV Turkey/98 Denizli VCRI-Pendik/Turkey Cell culture Turkey 1998 Goat
30 GTPV Oman/84 IAH-Pirbright/UK Cell culture Oman 1984 Goat
31 GTPV MOG/GP/T/4/08 IVM/Mongolia Skin scrapping Mongolia 2008 Goat
32 GTPV Yemen/83 IAH-Pirbright/UK Cell culture Yemen 1983 Goat
33 GTPV Towele/O17/2013 NAHDIC/Ethiopia Skin scrapping Ethiopia 2013 Goat
34 GTPV Halasya/G18/2013 NAHDIC/Ethiopia Skin scrapping Ethiopia 2013 Goat
35 LSDV Galesa/B12/2008 NAHDIC/Ethiopia Skin scrapping Ethiopia 2008 Cattle
36 LSDV Sodo/B24/2010 NAHDIC/Ethiopia Skin scrapping Ethiopia 2010 Cattle
37 LSDV Chilimo/B11/2008 NAHDIC/Ethiopia Skin scrapping Ethiopia 2008 Cattle
38 LSDV Ambo/B8/2008 NAHDIC/Ethiopia Skin scrapping Ethiopia 2008 Cattle
39 LSDV Toke/B6/2008 NAHDIC/Ethiopia Skin scrapping Ethiopia 2008 Cattle
40 LSDV Ginchi/B10/2008 NAHDIC/Ethiopia Skin scrapping Ethiopia 2008 Cattle
41 LSDV Sodo/B22/2010 NAHDIC/Ethiopia Skin scrapping Ethiopia 2010 Cattle
42 LSDV Adama/B4/2011 NAHDIC/Ethiopia Skin scrapping Ethiopia 2011 Cattle
43 LSDV Ziway/B3/2011 NAHDIC/Ethiopia Skin scrapping Ethiopia 2011 Cattle
44 LSDV Asella/B2/2011 NAHDIC/Ethiopia Skin scrapping Ethiopia 2011 Cattle
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and a final extension at 72 °C for 2 min. PCR products
were cheeked by electrophoresis on a 2% agarose gel for
1 h at 100 V.
Preparation of controls
The PCR amplicons of SPPV Denizli and SPPV Morocco
vaccine (Romanian vaccine strain) were selected to pre-
pare positive control plasmids, representing the field iso-
lates and vaccine strains respectively. For plasmid
preparation, each amplicon was purified and ligated into
pGEM-T Easy Vector Systems (Promega). The ligated
products were used to transform DH5α competent cells
(Invitrogen). Plasmids containing the inserts were purified
from the positive bacteria clones using the PureYield Plas-
mid Midiprep System (Promega) following the manufac-
turer’s instructions. The purified plasmids were sequenced
to confirm the presence of the correct target region and
quantified using the Quant-iTPicoGreen dsDNA Assay
Kit (Invitrogen) on a NanoDrop 3300 fluorospectrometer.
The concentration of the plasmids was determined follow-
ing the steps described by Lamien et al., (2011) and the
plasmids were kept at − 20 °C until analysis.
Analytical sensitivity and specificity of the assay
The analytical sensitivity of the method was assessed by
amplifying 10-fold serial dilutions, from107 to 100
copies/reaction, then follow by 80, 60, 40, 20, 10 and 1
copies/reaction dilutions, of plasmids containing the
corresponding target of SPPV Denizli and SPPV
Morocco vaccine. The lowest number of viral genome
copies that could be detected by the assay was recorded.
The specificity was evaluated by amplifying DNA extracted
from all available SPP vaccines and field isolates as well as
GTPV and LSDV isolates from various geographical regions
(Table 1). The genotype of each sample was confirmed using
a capripox species specific PCR (Gelaye et al., 2013). Add-
itionally, the specificity in amplifying only CaPVs was deter-
mined by attempting to amplify DNA extracted from Orf
virus (ORFV), Mycoplasma capricolum ssp. capripneumonia
(Mccp), Bovine herpes virus (BOHV), Bovine popular stoma-
titis virus (BPSV) and cDNA derived from peste des petits
ruminants (PPR) virus (Additional file 1: Table S1).
Sequence analysis
For all CaPVs used in this study, the targeted region of the
genome was sequenced to confirm the accuracy of the
assay. Thus, all amplified PCR products of the above
described PCR reactions were purified using Wizard SV
Gel and PCR Clean Up System (Promega) and sequenced
commercially by LGC Genomics (Germany). The sequence
data were edited and the fragments assembled using Vector
NTI 11.5 software (Invitrogen). Multiple sequence align-
ments were performed using the CLUSTALW algorithm
implemented in BioEdit 7.5 software package to compare
SPPV field isolates and vaccine strains. All sequences were
deposited in GenBank under accession number MG764242
to MG764286.
Results
Assay design and optimization
Primers were designed to amplify a region between the
DNA ligase gene and the VARV B22R homologue gene of
SPPV. The region was first selected based on the sequence
alignment of three SPPV publicly available full genome se-
quences and a draft genome sequence of the SPP Morocco
vaccine derived from the Romanian vaccine strain. The SPP
vaccine had an 84 bp nucleotide deletion as compared to
SPPV field isolates (Fig. 1). The initial evaluation of the
assay showed that the Morocco vaccine strain could be dif-
ferentiated from SPPV Denizli field isolate based on the size
difference of the produced PCR amplicons: 218 bp for the
vaccine strain and 302 bp for the SPPV field isolate. In the
subsequent steps, the assay was optimized and further
evaluated.
Evaluation of the assay
The optimal assay parameters are presented in Methods.
The optimised assay was further evaluated by testing 46
Table 1 List of capripoxvirus isolates used in this study (Continued)
Sample No. Isolate/Strain name Source Sample type Country Collection-date Host
45 LSDV Arsi/B1/2011 NAHDIC/Ethiopia Skin scrapping Ethiopia 2011 Cattle
46 LSDV Sundus/2012 CVRL/Sudan Skin scrapping Sudan 2012 Cattle
Abbreviations: VCRI Veterinary Control and Research Institute, LNERV-ISRA Laboratoire National de l’Elevage et de Recherches Vétérinaires, Institut Sénégalais de
Recherches Agricoles, INMV-LCV Institut National de la Médecine Vétérinaire, Laboratoire Central Vétérinaire, IVM Institute of Veterinary Medicine, IAH Institute for
Animal Health, PANVAC Pan African Veterinary Vaccine Centre, NAHDIC National Animal Health Diagnostic and Investigation Center, HSL-AGES High Security
Laboratory, Austrian Agency for Health and Food Safety, CVRL Central Veterinary Research Laboratories
Table 2 Primers used in this study. The length of the predicted amplicons are given
Primer name Sequences Length Amplicon size
SPPV_DIV_Fow 5’-ATCTGCTACAAGTTTTAACGAACTTA- 3’ 26 218 bp (SPPV vaccines)
SPPV_DIV_Rev 5’-TGAATGTGATCTCATATCCTTATTG-3’ 25 302 (SPPV field isolates and GTPV) and 336 (LSDV)
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CaPV isolates or clinical samples including 12 field iso-
lates of SPPV, 5 SPP vaccines, 13 field isolates of GTPV
and 15 field isolates of LSDV and 1 LSDV vaccine (Table
1). All 5 SPP vaccines produced 218 bp PCR products
while the SPPV field isolates produced a 302 bp product
(Fig. 2 and Additional file 2: Figure S1). The SPPV field
isolates could not be clearly differentiated from GTPVs and
LSDVs (Fig. 2 and Additional file 2: Figure S1).
Limit of detection and specificity of the assay
The limit of detection of the assay was evaluated by ampli-
fying 10-fold serial dilutions of plasmids as described in
Methods. The results showed that the limit of
detection for SPPV field isolates and vaccine strains
were 80 and 10 copies/reaction (Additional file 3: Figure
S2) respectively. The specificity of the assay was tested by
attempting to amplify non-capripoxvirus DNA from Orf
virus, Mycoplasma capricolum ssp. capripneumonia
(Mccp), Bovine herpes virus (BOHV), Bovine popular
stomatitis virus (BPSV) and cDNA from peste des petits
ruminant virus. No amplification was observed
(Additional file 4: Figure S3).
Sequencing of the PCR amplicons
All PCR amplicons were sequenced for further validation of
this PCR approach. The results of the multiple sequence
Fig. 1 Multiple sequence alignments showing a 84-nucleotide deletion in SPPV vaccines. The nucleotide sequences of the intergenic region located between
the DNA ligase gene and the VARV B22R homologue gene for 45 Capripoxviruses of this study and 7 other retrieved from Genbank were compared
Fig. 2 Gel picture of PCR products for selected capripoxvirus samples. The SPPV vaccines appear to be shorter than SPPV field isolates, GTPV and
LSDV due to the 84 bp sequence difference. The PCR products of 218 bp, 302 bp and 338 bp represent SPPV vaccine strains, SPPV field isolates/
GTPVs, and LSDVs respectively. MM: 50 bp DNA ladder; a: positive control plasmid of the SPPV field isolates; b: positive control plasmid of the
SPPV vaccine strain; c: Negative control; Lanes 4–7: SPPV vaccine strains (sample 1 to 4 of Table 1); Lanes 8–15: SPPV field isolates (sample 5 to 12
of Table 1); Lanes 16–21: GTPVs (sample 13 to 18 of Table 1), Lanes 22–25: LSDVs (sample 19 to 22 of Table 1)
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alignment showed the absence of the 84-nucleotide deletion
in all SPPV field isolates, GTPV and LSDV. Additionally, the
targeted region was found to be well conserved among the
SPPV field isolates and the SPPV vaccine strains except for
the 84 nucleotides deletion. Ten nucleotide variations were
observed between SPPV field isolates and GTPVs. LSDV se-
quences are longer than SPPV field isolates and GTPVs due
to an insertion of 34–36 nucleotides. GTPV Saudi Arabia ap-
peared to be a SPPV and SPPV Oman showed the GTPV
specific features. The vaccine KS1 (renamed in our paper as
LSDV KS-1) presented a 34-nucleotide insertion as most
LSDV of this study.
Discussion
In this study, we identified a suitable target in CaPV gen-
ome and developed a PCR method to discriminate SPP
vaccine strains from SPPV field isolates as well as from
other CaPVs.
By aligning the full genome sequences of SPPV field iso-
lates with the unpublished full genome of SPPV Morocco
vaccine, a Romanian strain, we identified a region of 84 bp
nucleotide deletion in the vaccine strains. Primers were
designed to amplify this intergenic region located between
the DNA ligase gene and the VARV B22R homologue
gene of CaPV. The sequencing of this region in SPPV vac-
cine strains and SPPV field isolates available for this study,
showed this deletion to be unique to the SPP vaccines de-
rived from the Romanian and the Yugoslavian RM/65
strains produced in Algeria, Egypt, Morocco and Senegal.
However, the sequence of the NISKHI vaccine, whose full
genome has been previously published [9] did not carry
such a deletion. Nevertheless, the use of the NISHKI
strain seems to be confined to Russia and countries of the
former Soviet Union such as Kazakhstan [10]. By using
the targeted intergenic region, the aim of this study was to
develop an assay to discriminate the live attenuated
Romanian and Yugoslavian RM/65 SPP vaccines strains
from virulent SPPV field isolates and other CaPVs.
Interestingly, Romanian and Yugoslavian RM/65 SPPV
vaccines produced amplicons of shorter lengths, as com-
pared to field isolates of SPPV and other CaPVs, and thus
could be easily discriminated from them. The assay was
found to be very specific and sensitive, and the accuracy
and reliability was confirmed by sequencing the corre-
sponding amplicons of SPP vaccine strains and SPPV,
GTPV and LSDV field isolates available for this study.
The high sensitivity of this assay for SPPV vaccine
strain, as compared to the field isolates, is likely due to
the shortest amplicon size in the vaccine strains. No
amplification was detected for any non-CaPV samples by
the assay. However, the assay could not differentiate
SPPV field isolates from LSDVs and GTPVs. Although
an insertion of 34–36 nucleotides was observed in all
LSDVs, making them longer than GTPVs and SPPV field
isolates, it was not possible to resolve these differences
on the agarose gel. Owing to the availability of species-
specific PCR [11–13] for CaPV genotype determination,
we suggest that the current assay could be used once the
genotype of CaPV is established. Alternatively, the exact
capripoxvirus genotype can be determined by sequen-
cing the region targeted in this study. Within the SPPV
genotype, the test, undoubtedly discriminates between
the virulent field isolates and the vaccines derived from
the Romanian and the Yugoslavian RM/65 strains.
The availability of an easy-to-use molecular method is
needed for the identification of SPPV, to rule out the involve-
ment of SPP vaccines following a CaP outbreak in previously
vaccinated flock of small ruminants. In Middle Eastern and
Asian countries, small ruminants are protected from CaPV
infections using various SPPV, GTPV or LSDV derived vac-
cines, however, SPP vaccines derived from Romanian and
the Yugoslavian RM/65 strains are predominant [14]. In Af-
rica, small ruminants are protected against CaPV using ei-
ther KSGP O-240 and O-180 vaccines or SPP vaccines
derived from the Romanian and the Yugoslavian RM/65
strains. Since KSGP O-240 and O-180 strains are of LSDV
genotype, the use of a CaPV species-specific assay [11–13]
can allow for determination of their involvement when the
disease occurs in a previously vaccinated herd. However, if a
herd is vaccinated with a SPP vaccine from the Romanian
and the Yugoslavian RM/65 strains, the full genome sequen-
cing of the viral isolate, collected during an outbreak, would
be required to rule out vaccine involvement when an out-
break occurs. This is time-consuming and cost prohibitive
for most laboratories in limited resourced countries. Thus,
the identification of suitable target in the viral genome to dif-
ferentiate SPPV vaccine strains from SPPV field isolates
greatly reduces the costs, by allowing the sequencing of small
specific genome fragments. Furthermore, this region can be
targeted in a simple molecular method such as the PCR
approach presented in the work, thereby avoiding the use of
sequencing. The current assay is intended to be used by all
veterinary laboratories, including those with limited re-
sources. It can also be used as a front-line tool for the direct
screening of pathological samples collected during CaPV
outbreaks, especially those occurring in previously vaccinated
small ruminant populations. A study was recently conducted
in Morocco to rule out the involvement of the vaccine strain
in 2010 SPP outbreaks using a PCR based approach [15].
When compared to the assay developed by Haegeman and
co-workers [15], our method presents the advantage of using
only one primer pair to target both viruses, and thus, is
much simpler to conduct and interpret. In addition, more
vaccine strains and field isolates, from various geographical
locations were included in this study, which broadened the
scope of the applicability to all countries where SPP vaccines
derived from the Romanian or the Yugoslavian RM/65
strains are used.
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Conclusions
The molecular assay described herein is a reliable and
rapid method that can easily be implemented for the dif-
ferentiation of SPP vaccine derived from the Romanian
or the Yugoslavian RM/65 strains from virulent SPPV
field isolates. The method is applicable as a routine tool
for outbreak investigations and disease surveillance in
both SPP and GTP enzootic and disease-free countries.
It is expected that its adoption by veterinary laboratories
in CaPV affected countries, will help facilitate the con-
trol and management of CaP disease in small ruminants.
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